(Total Views: 577)
Posted On: 01/05/2022 9:52:41 AM
Post# of 153988
While there is nothing regarding the 700 mg group, it seems they are comparing it to the previously blinded placebo arm.
“The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1. ”
This is different from the historical control group data discussed by Nader/Recknor previously.
I think this bodes very well for what we will see from 700 mg data.
“The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1. ”
This is different from the historical control group data discussed by Nader/Recknor previously.
I think this bodes very well for what we will see from 700 mg data.
(2)
(0)
